Freudenheim Partners announced that it arranged the relocation and expansion of Cyprotex, an Evotec company, from 313 Pleasant Street in Watertown to 200 Staples Drive in Framingham. Cyprotex is more than tripling in size and growing from its current space of approximately 8,000 SF and will occupy 30,000 SF on the 1st floor.
Ellie Cullinan represented the tenant, Cyprotex, while Tyler McGrail of Newmark represented the Landlord, Outshine Properties, in the transaction.
Cyprotex, fully owned by the rapidly growing life science company Evotec, engaged Freudenheim Partners to help them navigate a very complex environment. Due to a rapid expansion of their business in the US, they needed to find a facility with the ability to deliver state-of-the-art lab space on an ambitious timeline. Beyond the scientific needs, they were also looking for a location that offered the amenities to attract high quality employees, and they needed the flexibility to expand as their business continues to evolve.
Given the historically high prices and the lack of options in the market, Cyprotex leveraged Ellie’s expertise to help them understand what real estate solution would support the growth of their business.
“The challenge was finding space that would meet our clients’ needs from a scientific, economic and timing standpoint as well as offer the option to expand” said Ellie Cullinan, Executive Vice President of Freudenheim Partners. “200 Staples Drive not only checked those boxes but is in an attractive corporate setting with great area amenities” she added.
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “Integrating predictive toxicology and ADME research into the R&D continuum is a priority for the cost-efficient development of new medicines. Cyprotex’ expansion into a first-class scientific facility in Framingham will benefit both existing and new clients across the US. The co-location of Cyprotex’ offering in proximity to Evotec’s US East Coast sites, especially the sample management facility in Branford, CT, further allows us to drastically reduce turnaround times.”
200 Staples Drive, Framingham is a two-story, 60,000 square foot building located in 9/90 Corporate Center near Sanofi Genzyme and other life science industry leaders. The building provides excellent access to all major highways and provides MWTA shuttle service to the Framingham Commuter rail station. Additionally, only a short walk to many area amenities including cafe, daycare, health clubs and hotels.
About Cyprotex
Established in 1999, Cyprotex Limited was acquired by Evotec in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Framingham near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care, agrichemical and tobacco industries. Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during preclinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise. Further information on Cyprotex is available on our website at www.cyprotex.com. To learn more about Evotec please visit www.evotec.com.
About Freudenheim Partners:
A commercial real estate brokerage firm founded on the principle that strong relationships are built by consistently delivering the best results for our clients. FP brings creativity, thoughtful insight and superior execution to the forefront of each and every leasing and investment sales interaction.
For more information about Freudenheim Partners, please visit https://www.fpcre.com.
